TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 170 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,161,213 | -31.1% | 1,807,742 | +18.3% | 0.43% | -22.4% |
| Q2 2023 | $23,465,779 | -18.3% | 1,527,720 | +19.7% | 0.56% | -18.5% |
| Q1 2023 | $28,711,859 | +43.5% | 1,276,650 | +34.2% | 0.68% | +42.1% |
| Q4 2022 | $20,013,200 | -14.7% | 951,650 | 0.0% | 0.48% | -20.5% |
| Q3 2022 | $23,449,000 | +1.7% | 951,650 | 0.0% | 0.61% | -9.7% |
| Q2 2022 | $23,058,000 | -6.0% | 951,650 | 0.0% | 0.67% | +8.8% |
| Q1 2022 | $24,524,000 | -17.0% | 951,650 | 0.0% | 0.62% | -9.5% |
| Q4 2021 | $29,539,000 | -18.6% | 951,650 | -36.4% | 0.68% | -10.6% |
| Q3 2021 | $36,298,000 | +66.5% | 1,496,817 | +0.2% | 0.76% | +77.0% |
| Q2 2021 | $21,800,000 | -40.8% | 1,494,164 | +1.3% | 0.43% | -46.4% |
| Q1 2021 | $36,845,000 | +32.4% | 1,475,564 | +44.5% | 0.80% | +36.3% |
| Q4 2020 | $27,827,000 | – | 1,021,000 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,084,300 | $15,820,000 | 3.32% |
| ARMISTICE CAPITAL, LLC | 5,748,000 | $83,863,000 | 1.50% |
| RA Capital Management | 5,614,428 | $81,915,000 | 1.32% |
| Krensavage Asset Management, LLC | 140,000 | $2,043,000 | 0.69% |
| CM Management, LLC | 60,000 | $875,000 | 0.63% |
| Altium Capital Management LP | 170,484 | $2,487,000 | 0.58% |
| HighVista Strategies LLC | 53,498 | $781,000 | 0.55% |
| Sio Capital Management, LLC | 150,000 | $2,189,000 | 0.54% |
| MANGROVE PARTNERS IM, LLC | 295,037 | $4,305,000 | 0.44% |
| Rock Springs Capital Management LP | 1,494,164 | $21,800,000 | 0.43% |